A Look At Savara (SVRA) Valuation After Positive Phase 3 IMPALA 2 Data And MOLBREEVI Launch Preparations

Simply Wall St.

May 23

Savara (SVRA) is back in focus after new Phase 3 IMPALA-2 data showed its inhaled therapy molgramostim improved exercise capacity and reduced disease biomarkers in autoimmune pulmonary alveolar ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2637207893"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2637207893\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2637207893?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-05-23 22:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637207893","market":"sg","top_or_hot":-1,"title":"A Look At Savara (SVRA) Valuation After Positive Phase 3 IMPALA 2 Data And MOLBREEVI Launch Preparations","media":"Simply Wall St.","content":"<div>\n<p>Savara (SVRA) is back in focus after new Phase 3 IMPALA-2 data showed its inhaled therapy molgramostim improved exercise capacity and reduced disease biomarkers in autoimmune pulmonary alveolar ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/a-look-at-savara-svra-valuation-after-positive-phase-3-impal\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Savara (SVRA) Valuation After Positive Phase 3 IMPALA 2 Data And MOLBREEVI Launch Preparations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Savara (SVRA) Valuation After Positive Phase 3 IMPALA 2 Data And MOLBREEVI Launch Preparations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-23 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/a-look-at-savara-svra-valuation-after-positive-phase-3-impal><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Savara (SVRA) is back in focus after new Phase 3 IMPALA-2 data showed its inhaled therapy molgramostim improved exercise capacity and reduced disease biomarkers in autoimmune pulmonary alveolar ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/a-look-at-savara-svra-valuation-after-positive-phase-3-impal\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SVRA","symbol_name":"Savara Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/a-look-at-savara-svra-valuation-after-positive-phase-3-impal","article_id":"2637207893","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/a-look-at-savara-svra-valuation-after-positive-phase-3-impal","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2637207893","pubTimestamp":1779546462,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Savara (SVRA) is back in focus after new Phase 3 IMPALA-2 data showed its inhaled therapy molgramostim improved exercise capacity and reduced disease biomarkers in autoimmune pulmonary alveolar proteinosis patients.\nSee our latest analysis for Savara.\nDespite a modest pullback in the 1 day and 90 day share price returns, Savara’s stock has delivered a 1 year total shareholder return of 76.76% and a 5 year total shareholder return of 178.89%. These figures reflect how investors have reacted to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SVRA":"Savara Inc","BK4139":"生物科技"},"translate_title":"在积极的3期IMPALA 2数据和MOLBREEVI发布准备工作之后，看看Savara(SVRA)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SVRA":1.5},"content_text":"Savara (SVRA) is back in focus after new Phase 3 IMPALA-2 data showed its inhaled therapy molgramostim improved exercise capacity and reduced disease biomarkers in autoimmune pulmonary alveolar proteinosis patients. See our latest analysis for Savara. Despite a modest pullback in the 1 day and 90 day share price returns, Savara’s stock has delivered a 1 year total shareholder return of 76.76% and a 5 year total shareholder return of 178.89%. These figures reflect how investors have reacted to recent Phase 3 data, launch preparation updates for MOLBREEVI and the latest quarterly loss. If you are looking beyond a single rare disease stock, this could be a useful moment to see what else is shaping the future of medicine and technology through 34 healthcare AI stocks After such strong multi year returns, but a pullback of around 10% year to date and a last close of US$5.02 against an analyst target of US$10.81, are you seeing a fresh opportunity here, or are markets already pricing in future growth? AdvertisementPreferred Price-to-Book of 7.2x: Is it justified? On a P/B basis, Savara currently trades at 7.2x, which sets a high bar for expectations compared to both its peers and the broader US Biotechs industry. The P/B ratio compares the company’s market value to its book value, so a higher multiple often reflects strong confidence in future assets, profitability or both. For a clinical stage biopharmaceutical business with no meaningful revenue and ongoing losses, a high P/B usually signals that investors are heavily focused on potential future cash flows rather than current fundamentals. Here, Savara’s P/B of 7.2x is described as expensive versus a peer average of 6.4x. This suggests the stock is priced at a premium even within its own comparison group. Against the wider US Biotechs industry average of 2.4x, the gap is even wider. This reinforces the idea that expectations for the pipeline and future revenue are materially higher than what the balance sheet alone might justify. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 7.2x (OVERVALUED) However, investors still face key risks, including the company’s ongoing losses of US$129.482 million and its complete reliance on a single clinical stage asset. Find out about the key risks to this Savara narrative. Next Steps Mixed signals so far, with both risks and rewards on the table, mean this is a good time to inspect the details yourself and move quickly. Start with 1 key reward and 2 important warning signs. Looking for more investment ideas? If you stop with just one stock, you risk missing other opportunities that could fit your style, your risk tolerance and your time horizon.  Spot potential bargains that balance quality with price by scanning 49 high quality undervalued stocks. Prioritize resilience and sleep easier at night by focusing on 66 resilient stocks with low risk scores. Hunt for lesser known opportunities with solid fundamentals using the screener containing 21 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}